Most Popular

1
Now is no time to add pressure on businesses: top executives
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
3
Seoul to host winter festival from Dec. 13
4
Nationwide rail disruptions feared as union plans strike from Dec. 5
5
Blackpink's solo journeys: Complementary paths, not competition

6
N. Korea, Russia court softer image: From animal diplomacy to tourism
7
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
8
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
9
Korean Air offers special flights for mileage users
10
Defense ministry denies special treatment for BTS’ V amid phone use allegations

NewsletterSubscribe

Start your day with a roundup of key stories from The Korea Herald with news and comment on all that’s happening in Korea.

Green Cross LabCell’s IPO price set at 18,500 won

By Korea Herald

Published : June 14, 2016 - 16:58

- Link copied

[THE INVESTOR] Green Cross LabCell Corp. – a Green Cross affiliate that develops drugs for fighting incurable diseases – has officially priced its initial public offering at 18,500 won ($15.70), which is higher than previously indicated ranges, the company said on June 13.

Green Cross LabCell will raise 37 billion won with the IPO. The market capitalization of the firm is expected to reach around 195.2 billion won.

Its shares will be listed on the tech-heavy Kosdaq index on June 23.

The firm, which is one of Green Cross’ health care arms, developed MG4101, an allogeneic natural killer cell line.

By Kim Ji-hyun (jemmie@heraldcorp.com)

Korea Herald
Korea Herald
Articles by Korea Herald

Green Cross LabCell’s IPO price set at 18,500 won

More from Headlines